医学
血栓调节蛋白
内科学
心房颤动
纤维蛋白原
血管性血友病因子
纤溶酶原激活剂
胃肠病学
抗凝血酶
纤溶
蛋白质C
纤溶酶原激活物抑制剂-1
心脏病学
凝血酶
血小板
肝素
作者
Alexander Weymann,Anton Sabashnikov,Sadeq Ali-Hasan-Al-Saegh,Aron‐Frederik Popov,Seyed Jalil Mirhosseini,William L. Baker,Mohammadreza Lotfaliani,Tong Liu,Hamidreza Dehghan,Şenol Yavuz,Michel Pompeu Sá,Jae‐Sik Jang,Mohamed Zeriouh,Lei Meng,Fabrizio D’Ascenzo,Abhishek Deshmukh,G. Biondi-Zoccai,Pascal M. Dohmen,Hugh Calkins
出处
期刊:PubMed
日期:2017-03-31
卷期号:23: 97-140
被引量:34
标识
DOI:10.12659/msmbr.902558
摘要
BACKGROUND The pathophysiological mechanism associated with the higher prothrombotic tendency in atrial fibrillation (AF) is complex and multifactorial. However, the role of prothrombotic markers in AF remains inconclusive. MATERIAL AND METHODS We conducted a meta-analysis of observational studies evaluating the association of coagulation activation, fibrinolytic, and endothelial function with occurrence of AF and clinical adverse events. A comprehensive subgroup analysis and meta-regression was performed to explore potential sources of heterogeneity. RESULTS A literature search of major databases retrieved 1703 studies. After screening, a total of 71 studies were identified. Pooled analysis showed the association of coagulation markers (D-dimer (weighted mean difference (WMD) =197.67 and p<0.001), fibrinogen (WMD=0.43 and p<0.001), prothrombin fragment 1-2 (WMD=0.53 and p<0.001), antithrombin III (WMD=23.90 and p=0.004), thrombin-antithrombin (WMD=5.47 and p=0.004)); fibrinolytic markers (tissue-type plasminogen activator (t-PA) (WMD=2.13 and p<0.001), plasminogen activator inhibitor (WMD=11.44 and p<0.001), fibrinopeptide-A (WMD=4.13 and p=0.01)); and endothelial markers (von Willebrand factor (WMD=27.01 and p<0.001) and soluble thrombomodulin (WMD=3.92 and p<0.001)) with AF. CONCLUSIONS The levels of coagulation, fibrinolytic, and endothelial markers have been reported to be significantly higher in AF patients than in SR patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI